Chapter: Major Depressive Disorder

1. Design initial pharmacotherapy on the basis of patient presentation and current treatment guidelines for major depressive disorder.
2. Assess treatment goals for a patient with major depressive disorder based on rating scales, clinical presentation, and diagnostic specifiers.
3. Develop a pharmacotherapy plan based on inadequate response to antidepressant treatment.
4. Account for differences in pharmacotherapy selection based on special population characteristics. 

Chapter: Bipolar Disorder

1. Design a guideline-based pharmacotherapy plan for a patient with bipolar mania.
2. Design a guideline-based pharmacotherapy plan for a patient with bipolar depression.
3. Design a guideline-based pharmacotherapy plan for a bipolar patient with mixed features.
4. Evaluate the place in therapy of antidepressants for bipolar disorder.
5. Develop a comprehensive treatment plan for patients in special populations with bipolar disorder. 

Chapter: Schizophrenia and Antipsychotic-Induced Movement Disorders

1. Evaluate a patient-centered treatment plan to ensure it is aligned with best practices per guideline recommendations.
2. Distinguish when a new antipsychotic versus an older agent may be beneficial in treating schizophrenia for an individual patient.
3. Design patient conversion to a different formulation of an antipsychotic when need or patient preference dictates.
4. Assess the risk versus benefit of adding a medication to treat a drug-induced movement disorder to an existing pharmacotherapy regimen. 

Chapter: Anxiety and Related Disorders

1. Evaluate clinical severity of generalized anxiety disorder (GAD), panic disorder (PD), posttraumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD) based on clinical assessment scales and patient presentation.
2. Design appropriate pharmacotherapeutic and/or psychotherapeutic interventions for the treatment of GAD, PD, PTSD, and OCD
3. Evaluate the place in therapy of benzodiazepines for GAD, PD, PTSD, and OCD
4. Develop a comprehensive treatment plan for anxiety and related disorders based on individual patient characteristics

Chapter: Eating Disorders

1. Differentiate clinical presentations of the following eating disorders: anorexia nervosa, bulimia nervosa, binge eating disorder, and avoidant/restrictive food intake disorder.
2. Evaluate the appropriateness of nonpharmacologic treatments in patients with eating disorders.
3. Apply appropriate laboratory and intake monitoring for a patient at risk for refeeding syndrome.
4. Design a patient-centered pharmacotherapy treatment and monitoring plan for a patient with bulimia nervosa.
5. Devise a patient-centered pharmacotherapy treatment and monitoring plan for a patient with binge eating disorder.
6. Evaluate the appropriateness of pharmacotherapy for the management of anorexia nervosa and avoidant/restrictive food intake disorders. 

Chapter: Attention-Deficit/Hyperactivity Disorder

1. Apply treatment guideline recommendations for attention-deficit/hyperactivity disorder (ADHD) in child, adolescent, and adult populations.
2. Evaluate pharmacokinetic differences of recently approved ADHD medications.
3. Analyze clinically relevant drug-drug, drug-food, and disease-drug interactions in a patient with ADHD.
4. Develop a comprehensive treatment plan for patients with ADHD and common comorbid psychiatric conditions.

Interactive Case: Precision Medicine in Psychiatry

1. Evaluate the evidence and guideline recommendations for pharmacogenomic (PGx) testing and therapeutic drug monitoring (TDM) in psychiatry.
2. Distinguish when a patient may benefit from PGx testing and TDM in psychiatry.
3. Assess psychiatric PGx and TDM results in a patient with mental illness.
4. Develop a treatment plan, including patient counseling, using PGx and/or TDM results for a patient with mental illness. 

Interactive Case: Clinical Pearls of Clozapine

1. Develop a treatment plan involving clozapine using current evidence and clinical guidelines.
2. Assess patients for potential clinically relevant drug interactions with clozapine.
3. Justify the role of monitoring clozapine and norclozapine serum concentrations in clinical practice.
4. Account for potential clozapine-related adverse events during and after an acute hospital admission.